SALARIUS PHARMACEUTICALS SLRX 深 沪
已收盘 12-05 16:00:00 美东时间
0.825
-0.045
-5.23%
华盛通- 最 高0.91
- 今 开0.91
- 成交量 58.50万股
- 最 低 0.822
- 昨 收 0.8705
- 总市值 77.93万
- 52周最高 108.00
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 0.7106
- 委 比 54.88%
- 总股本 94.46万
- 历史最高 44445.00
- 量 比 1.89
- 振 幅 10.11%
- 历史最低 0.822
- 每 手 1
- 风险率 9.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Salarius' Decoy Therapeutics Announces Collaboration To Conduct In Vitro Testing Of Decoy's Peptide Conjugate Fusion Inhibitors Across Several Influenza Strains Including H5N1 Avian Flu
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting
12-01 21:03
Salarius Pharma Cites Error On S&P CapIQ Platform; Reiterates Active Nasdaq Trading Under SLRX Ticker
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under
11-20 03:47
3 Penny Stocks to Watch Now, 11/13/25
Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are the 3...
11-13 23:02
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Salarius Pharmaceuticals and Decoy Therapeutics have completed their strategic merger, with the combined company focused on advancing Decoy’s peptide conjugate therapeutics via its IMP3ACT platform. The merger provides the company with $14 million in pro forma cash after the merger and recent public offering. Decoy’s technology enables rapid drug design and manufacturing, targeting unmet medical needs in areas like respiratory infectious diseases...
11-13 13:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
11-13 01:05
Shoulder Innovations (SI) Stock Rose 21% After-Hours: Here's Why
Shoulder Innovations shares jumped more than 21% in after-hours trading Tuesday after the company posted strong quarterly results and raised its 2025 revenue forecast.
11-12 15:33
Salarius stock slides after pricing $7M offering
Salarius Pharmaceuticals (SLRX) has priced an offering to raise $7M in gross proceeds. The offering includes 2.5M common shares and pre-funded warrants to purchase 2.15M shares, each paired with Serie...
11-12 01:02
Salarius Prices $7M Public Offering Of 2,514,335 Shares And Pre Funded Warrants To Purchase 2,152,331 Shares Of Common Stock At A Combined Price Of $1.50
Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ:SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting
11-11 22:20
Salarius Pharmaceuticals Approves CEO Bonus for Merger
Salarius Pharmaceuticals ( ($SLRX) ) has shared an announcement. On October 21,...
10-22 00:18
